J Bone Joint Surg Am. 2005 May;87(5):1129-36.
http://www.ncbi.nlm.nih.gov/entrez/q..._uids=15866981
Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery.
Kokoszka A, Kuflik P, Bitan F, Casden A, Neuwirth M.
Spine Institute, Beth Israel Medical Center, New York, NY 10003, USA.
agnieszka.kokoszka@mail.hsc.sunysb.edu
Aprotinin is a serine protease inhibitor with antifibrinolytic properties that has been approved as a blood-conserving drug in cardiac surgery by the United States Food and Drug Administration. On the basis of the current evidence from Level-I trials, we make a grade-A recommendation for use of the high-dose aprotinin regimen in hip and spine surgery. Because of conflicting data, the low-dose aprotinin therapy as well as the use of aprotinin in patients with cancer cannot be recommended (grade-I recommendation). High-quality randomized trials are necessary to determine the optimal (and minimal) therapeutic dose of aprotinin and the optimal time of aprotinin administration during surgery.
PMID: 15866981 [PubMed - in process]
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
